Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the company’s ...

Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:SAGE) that it does not already owned by Biogen for $7.22 per share.

The agreement complements Biogen's early-stage immunology pipeline by adding an oral mechanism with potential applicability across multiple immune-mediated diseases. C5aR1 plays a pivotal role in ...

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The following table summarizes their recent ...

Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:BIIB), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...